☆ 4.7 Review

COVID-19 Research: Lessons from Non-Human Primate Models

VACCINES (2021)

Related references

Note: Only part of the references are listed.

Letter Immunology

Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection by a Phylogenetically Distinct Strain

Jan Van Elslande et al.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing

Kelvin Kai-Wang To et al.

Summary: The study confirmed reinfection in an apparently immunocompetent patient 142 days after the first symptomatic episode, rather than persistent viral shedding. This suggests that SARS-CoV-2 may continue to circulate among humans, even with natural herd immunity, highlighting the need for further research on protective immunological correlates for vaccine design.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Review Microbiology

Remdesivir against COVID-19 and Other Viral Diseases

Jakob J. Malin et al.

Summary: Remdesivir is the first approved treatment for COVID-19, showing therapeutic and prophylactic effects in animal models of various viruses. However, it failed in a clinical trial on ebolavirus disease but showed beneficial effects for patients with COVID-19 in a placebo-controlled trial.

CLINICAL MICROBIOLOGY REVIEWS (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Shengli Xia et al.

Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Infectious Diseases

What reinfections mean for COVID-19

Akiko Iwasaki

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Genomic evidence for reinfection with SARS-CoV-2: a case study

Richard L. Tillett et al.

Summary: A man was infected with SARS-CoV-2 twice with genetically different virus variants, the second infection being more severe. The study suggests that previous exposure to SARS-CoV-2 may not guarantee immunity, and all individuals should take precautions to avoid infection. This has implications for vaccine development and application.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Review Microbiology

Characteristics of SARS-CoV-2 and COVID-19

Ben Hu et al.

Summary: This review summarizes the research progress on SARS-CoV-2 and COVID-19, including virology characteristics, pathogenesis, and recent advances in treatment methods. Furthermore, it discusses in detail the potential wildlife hosts and zoonotic origin of this emerging virus.

NATURE REVIEWS MICROBIOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Lauren B. Rodda et al.

Summary: The study found that individuals recovered from mild COVID-19 develop sustained SARS-CoV-2-specific immunological memory for at least 3 months, including immunoglobulin antibodies, neutralizing plasma, and memory B and T cells. These memory lymphocytes exhibit potent antiviral function, aiding in immune defense.

CELL (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Adaptive immunity to SARS-CoV-2 and COVID-19

Alessandro Sette et al.

Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection

Philip J. M. Brouwer et al.

Summary: The study introduces a nanoparticle vaccine displaying multiple copies of the SARS-CoV-2 spike protein, which successfully induced potent antibody responses in mice, rabbits, and cynomolgus macaques. The vaccine-induced immunity protected macaques against a high-dose challenge, showing promising potential as a candidate to curtail the COVID-19 pandemic.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

Timothy N. Hoang et al.

Summary: The study found that in a rhesus macaque model of SARS-CoV-2 infection, baricitinib did not reduce viral shedding, but did decrease inflammation and suppress the production of cytokines and chemokines, suggesting its potential as an effective treatment for COVID-19 inflammation.

CELL (2021)

Add to Collection

Article Cell Biology

Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models

Gan Wang et al.

Summary: A potential anti-COVID-19 drug candidate, dalbavancin, was discovered based on virtual screening of an FDA-approved peptide drug library and in vitro and in vivo functional antiviral assays. Dalbavancin was found to directly bind to human ACE2, blocking its interaction with the SARS-CoV-2 spike protein and effectively preventing viral replication in cells. Studies in mouse and rhesus macaque models showed that dalbavancin significantly inhibited viral replication and histopathological injuries caused by SARS-CoV-2 infection, indicating its promising potential as an anti-COVID-19 drug candidate.

CELL RESEARCH (2021)

Add to Collection

Article Immunology

Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease 2019

Jee-Soo Lee et al.

Summary: The study found that recovered COVID-19 patients may be at risk of reinfection with a different strain of SARS-CoV-2, as the viral genome of reinfection differed from the initial infection. This suggests that SARS-CoV-2 infection may not provide immunity against other strains of SARS-CoV-2.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Gastroenterology & Hepatology

The Gastrointestinal Tract Is an Alternative Route for SARS-CoV-2 Infection in a Nonhuman Primate Model

Li Jiao et al.

Summary: This study in a rhesus monkey model found that both intranasal and intragastric inoculation with SARS-CoV-2 led to pneumonia and gastrointestinal dysfunction, with inflammatory cytokines possibly playing a role in connecting the respiratory and digestive systems in disease pathogenesis.

GASTROENTEROLOGY (2021)

Add to Collection

Review Medicine, General & Internal

COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs

Alessandra Bartoli et al.

Summary: There is currently no specific therapy for COVID-19 disease, and clinical studies have methodological limitations. Different categories of drugs have varying efficacy at different stages of the disease, emphasizing the need for further well-designed clinical trials to establish a standard of care for COVID-19.

INTERNAL AND EMERGENCY MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Robert L. Gottlieb et al.

Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella et al.

Summary: The BBV152 vaccine demonstrated tolerable safety outcomes and enhanced immune responses in this clinical trial, leading to selection of both Algel-IMDG formulations for phase 2 immunogenicity trials. Further efficacy trials are warranted to validate the vaccine's effectiveness.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Correlates of protection against SARS-CoV-2 in rhesus macaques

Katherine McMahan et al.

Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.

NATURE (2021)

Add to Collection

Article Immunology

Establishment of an African green monkey model for COVID-19 and protection against re-infection

Courtney Woolsey et al.

Summary: African green monkeys infected with SARS-CoV-2 exhibit symptoms closely resembling those in humans, making them a valuable model for studying COVID-19 pathogenesis and testing medical interventions.

NATURE IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Article Cell Biology

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Delphine Sterlin et al.

Summary: The study found that humoral immune responses to SARS-CoV-2 infection are dominated by IgA antibodies, with specific IgA plasmablasts rapidly expanding shortly after symptom onset and peaking in the third week of the disease. Virus-specific antibody responses include IgG, IgM, and IgA, with IgA playing a greater role in virus neutralization compared to IgG.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques

Yashavanth Shaan Lakshmanappa et al.

Summary: Induction of CD4 T follicular helper (Tfh) cells is crucial for antibody responses to viral infections, as shown in a rhesus macaque model of mild COVID-19 where SARS-CoV-2 infection resulted in transient accumulation of proliferating Tfh cells with a Th1 profile in peripheral blood and the generation of germinal center Tfh cells specific for viral proteins.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Jing-Hui Tian et al.

Summary: The study reports the development of a SARS-CoV-2 subunit vaccine candidate that contains full-length spike protein stabilized in its prefusion conformation, showing immunogenicity in mice and protection in baboons with Matrix-M adjuvanted vaccine, supporting ongoing phase 1/2 clinical evaluation of NVX-CoV2373 with Matrix-M (NCT04368988).

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Cell Biology

D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction

Sophie M-C Gobeil et al.

Summary: The study found that the mutation variant G614 of SARS-CoV-2 leads to significant changes in the protein structure, resulting in altered positioning ratio of RBD, which may have implications for vaccine design.

CELL REPORTS (2021)

Add to Collection

Article Microbiology

Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets

Dhiraj Kumar Singh et al.

Summary: Non-human primate models, particularly macaques and baboons, demonstrate acute respiratory distress and immune responses similar to COVID-19 progression in humans, making them valuable for testing vaccines and therapies. Age appears to affect viral shedding, lung inflammation, and immune response in these animal models.

NATURE MICROBIOLOGY (2021)

Add to Collection

Article Pathology

Acute Respiratory Distress in Aged, SARS-CoV-2-Infected African Green Monkeys but Not Rhesus Macaques

Robert V. Blair et al.

Summary: This study reported two cases of ARDS in AGMs infected with SARS-CoV-2, as well as a comparatively mild COVID-19 phenotype in two surviving AGMs and four infected RMs. The results suggest that aged AGMs may be useful for modeling severe disease manifestations related to COVID-19.

AMERICAN JOURNAL OF PATHOLOGY (2021)

Add to Collection

Letter Immunology

Severe Reinfection With South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant 501Y.V2

Noemie Zucman et al.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Medicine, General & Internal

SARS-CoV-2 variants and ending the COVID-19 pandemic

Arnaud Fontanet et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Peter Richmond et al.

Summary: A study in Australia evaluated the dose-finding and adjuvant justification of the SCB-2019 vaccine against SARS-CoV-2. The vaccine, which contains a stabilised trimeric form of the spike protein (S-Trimer) combined with AS03 or CpG/Alum adjuvants, elicited robust humoral and cellular immune responses in both younger and older adults.

LANCET (2021)

Add to Collection

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu et al.

Summary: The study showed that CoronaVac vaccine is safe and well tolerated in older adults, and is able to induce neutralizing antibody levels. The highest dose of 3 μg of the vaccine can generate neutralizing antibody levels similar to the 6 μg dose, supporting the use of the 3 μg dose CoronaVac in phase 3 trials.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella et al.

Summary: BBV152 vaccine, consisting of whole-virion inactivated SARS-CoV-2 with Algel and IMDG, showed high neutralizing antibody responses in phase 1 trial and better reactogenicity in phase 2 trial. The 6 mu g with Algel-IMDG formulation has been chosen for phase 3 efficacy trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Annette B. Vogel et al.

Summary: The two vaccine candidates, BNT162b1 and BNT162b2, developed contain modified messenger RNA encoding immunogens derived from the spike glycoprotein of SARS-CoV-2. They have shown promising immune responses in mice and rhesus macaques, with ongoing phase I trials in Germany and the USA and a global phase II/III trial for BNT162b2.

NATURE (2021)

Add to Collection

Letter Medicine, General & Internal

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Kai Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure

Sara C. Johnston et al.

Summary: Airborne transmission of SARS-CoV-2 is found to be a prevalent route of human exposure. In a study comparing African green monkeys, rhesus macaques, and cynomolgus macaques exposed to the virus, respiratory abnormalities and viral shedding were observed in all animals. Fever was noted in cynomolgus macaques, while African green monkeys and rhesus macaques experienced thrombocytopenia. The findings suggest that macaques, in addition to African green monkeys, can serve as successful natural transmission models for evaluating medical countermeasures.

PLOS ONE (2021)

Add to Collection

Article Virology

Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques

Hirohito Ishigaki et al.

Summary: Cynomolgus macaques were used to establish an animal model of COVID-19 to develop vaccines and antiviral drugs, showing similar symptoms to human patients. The study found that both neutralizing antibodies and cellular immunity play important roles in eliminating SARS-CoV-2.

VIROLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19

Francisco J. Salguero et al.

Summary: This study demonstrates that SARS-CoV-2 replicates in the upper and lower respiratory tract of both rhesus and cynomolgus macaques, causing pulmonary lesions. Immune responses against SARS-CoV-2 are similar in both species, suggesting that both macaque species authentically represent mild to moderate forms of COVID-19. The findings provide valuable insights for evaluating interventions against SARS-CoV-2.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

Joshua G. Liang et al.

Summary: Researchers have developed a trimeric vaccine candidate S-Trimer for COVID-19 based on Trimer-Tag technology. Immunization studies in animal models showed high levels of neutralizing antibodies and cellular immune responses, and protection from SARS-CoV-2 challenge in rhesus macaques. This technology may be crucial for scalable production of subunit vaccines against emerging RNA viruses.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Multidisciplinary Sciences

Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans

P. J. Klasse et al.

Summary: This article summarizes the progress of multiple preventive vaccines being developed to counter the COVID-19 pandemic, including results from animal and human trials as well as challenge experiments. The focus is on comparing the immunogenicity performance of the vaccines and summarizing the press releases on vaccine efficacy trials.

SCIENCE ADVANCES (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Shilong Yang et al.

Summary: The results from Phase 1 and Phase 2 trials of the COVID-19 vaccine ZF2001 show that the vaccine is well tolerated and immunogenic, supporting the use of a 25 microgram dose in a three-dose schedule for large-scale evaluation in a Phase 3 trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Post-acute COVID-19 syndrome

Ani Nalbandian et al.

Summary: SARS-CoV-2 is responsible for the COVID-19 pandemic, causing global healthcare crises. Recovery from COVID-19 may lead to persistent symptoms and long-term complications, prompting the need for multidisciplinary care and follow-up for survivors.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. A. Madhi et al.

Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cell Biology

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Bryan E. Jones et al.

Summary: LY-CoV555 is a novel neutralizing antibody derived from a convalescent patient with COVID-19, showing high affinity binding, potent inhibition of ACE2 binding, and strong neutralizing activity. This antibody has entered clinical trials and is being evaluated for various COVID-19 prevention and treatment indications.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Immunology

Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in Healthy Adults

Yanchun Che et al.

Summary: This study evaluated an inactivated SARS-CoV-2 vaccine for immunogenicity and safety in adults aged 18-59 years. The results showed that vaccinated adults developed neutralizing antibodies as well as anti-S/N antibodies with a low rate of adverse reactions.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Letter Immunology

Confirmed Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant VOC-202012/01

David Harrington et al.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Letter Immunology

Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil

Carolina Kymie Vasques Nonaka et al.

Summary: The case of reinfection from distinct virus lineages in Brazil with the E484K mutation raises concerns about the duration of protective immune responses against SARS-CoV-2, especially with the variant associated with escape from neutralizing antibodies. This highlights potential challenges for virus control measures.

EMERGING INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Pablo Tebas et al.

Summary: The study found that the INO-4800 vaccine performed well in inducing immune responses and had good safety, with no serious adverse events reported. Participants exhibited both cellular and humoral immune responses to the vaccine, indicating its effectiveness in eliciting immunity.

ECLINICALMEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Timothy P. Sheahan et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Markus Hoffmann et al.

CELL (2020)

Add to Collection

Review Biochemistry & Molecular Biology

COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons

Shivraj Hariram Nile et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2020)

Add to Collection

Review Medicine, Research & Experimental

A new threat from an old enemy: Re-emergence of coronavirus (Review)

Anca Oana Docea et al.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Abishek Chandrashekar et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Development of an inactivated vaccine candidate for SARS-CoV-2

Qiang Gao et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

Barry Rockx et al.

SCIENCE (2020)

Add to Collection

Article Engineering, Environmental

Presence of SARS-Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in the Early Stage of the Epidemic in The Netherlands

Gertjan Medema et al.

ENVIRONMENTAL SCIENCE & TECHNOLOGY LETTERS (2020)

Add to Collection

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

Vincent J. Munster et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Hui Wang et al.

CELL (2020)

Add to Collection

Article Cell Biology

Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques

Chao Shan et al.

CELL RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti et al.

LANCET (2020)

Add to Collection

Review Pharmacology & Pharmacy

COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials

Rohan Chakraborty et al.

BIOCHEMICAL PHARMACOLOGY (2020)

Add to Collection

Review Microbiology

Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics

Jay A. Grobler et al.

CELL HOST & MICROBE (2020)

Add to Collection

Article Multidisciplinary Sciences

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Brandi N. Williamson et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Noe B. Mercado et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Neeltje van Doremalen et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Pauline Maisonnasse et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Kizzmekia S. Corbett et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Mental Health and the Covid-19 Pandemic

Betty Pfefferbaum et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

Wei Deng et al.

SCIENCE (2020)

Add to Collection

Article Environmental Sciences

COVID-19 outbreak: Migration, effects on society, global environment and prevention

Indranil Chakraborty et al.

SCIENCE OF THE TOTAL ENVIRONMENT (2020)

Add to Collection

Letter Infectious Diseases

Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients

Valeria Cento et al.

JOURNAL OF INFECTION (2020)

Add to Collection

Review Multidisciplinary Sciences

SARS-CoV-2 vaccines in development

Florian Krammer

NATURE (2020)

Add to Collection

Review Multidisciplinary Sciences

Animal models for COVID-19

Cesar Munoz-Fontela et al.

NATURE (2020)

Add to Collection

Article Biotechnology & Applied Microbiology

Measurement of SARS-CoV-2 RNA in wastewater tracks community infection dynamics

Jordan Peccia et al.

NATURE BIOTECHNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Alina Baum et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Qian Zhang et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Paul Bastard et al.

SCIENCE (2020)

Add to Collection

Article Immunology

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre-Xabier et al.

VACCINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural and functional modelling of SARS-CoV-2 entry in animal models

Greg N. Brooke et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Article Microbiology

SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and shedding of infectious virus from both respiratory and gastrointestinal tracts

Amy L. Hartman et al.

PLOS PATHOGENS (2020)

Add to Collection

Review Critical Care Medicine

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

Daniel E. Leisman et al.

LANCET RESPIRATORY MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates

M. D. Fahlberg et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Letter Infectious Diseases

A case of SARS-CoV-2 reinfection in Ecuador

Belen Prado-Vivar et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Article Multidisciplinary Sciences

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys

Shuang Wang et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Review Immunology

Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models

David S. Khoury et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

Article Microbiology

Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: A nonhuman primate model of COVID-19 progression

Huiwen Zheng et al.

PLOS PATHOGENS (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Comparison of nonhuman primates identified the suitable model for COVID-19

Shuaiyao Lu et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection

Article Zoology

Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques

Tian-Zhang Song et al.

ZOOLOGICAL RESEARCH (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Age-related rhesus macaque models of COVID-19

Pin Yu et al.

ANIMAL MODELS AND EXPERIMENTAL MEDICINE (2020)

Add to Collection

Review Immunology

Nonhuman primate models of human viral infections

Jacob D. Estes et al.

NATURE REVIEWS IMMUNOLOGY (2018)

Add to Collection

Article Immunology

An Animal Model of MERS Produced by Infection of Rhesus Macaques With MERS Coronavirus

Yanfeng Yao et al.

JOURNAL OF INFECTIOUS DISEASES (2014)

Add to Collection

Article Microbiology

Infection with MERS-CoV Causes Lethal Pneumonia in the Common Marmoset

Darryl Falzarano et al.

PLOS PATHOGENS (2014)

Add to Collection

Article Multidisciplinary Sciences

Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques

Emmie de Wit et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Add to Collection

Article Medicine, General & Internal

Cynomolgus macaque as an animal model for severe acute respiratory syndrome

James V. Lawler et al.

PLOS MEDICINE (2006)

Add to Collection

Article Oncology

An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus

C Qin et al.

JOURNAL OF PATHOLOGY (2005)

Add to Collection

Article Virology

Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys

J McAuliffe et al.

VIROLOGY (2004)

Add to Collection

Article Oncology

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

I Hamming et al.

JOURNAL OF PATHOLOGY (2004)

Add to Collection

Article Virology

Macaque model for severe acute respiratory syndrome

T Rowe et al.

JOURNAL OF VIROLOGY (2004)

Add to Collection

Article Virology

Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2

WH Li et al.

JOURNAL OF VIROLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.